Influence of argatroban on major adverse cardiovascular and cerebrovascular events (MACCE) in patients with acute cerebral infarction
DAI Xiao-jie
DONG Su-juan
JIA Yi
Abstract：Objective To discuss the influence of argatroban on major adverse cardiovascular and cerebrovascular events (MACCE) in patients with acute cerebral infarction.Methods The patients (n=110) were chosen from the Department of Neurology of Xi’an Gaoxin Hospital from Jun. 2010 to Feb. 2015, and then divided randomly into treatment group and control group (eachn=55). All patients were given therapies of anti-hypertension, lowering blood fat and blood sugar, improving circulation, anti-platelet and expanding volume, and treatment group was additionally given argatroban for adjuvant treatment for 10 d.Results The effective rate was 89.1% in treatment group and 80.0% in control group (P<0.05). The platelet aggregation rate (PAG) decreased significantly in 2 groups after treatment (P<0.05), and PAG was significantly lower in treatment group than that in control group (P<0.05). The incidence of MACCE (hemorrhagic infarction, heart failure, transient ischemia and target vessel revascularization) was significantly lower in treatment group than that in control group (P<0.05) after following up for 3 m.Conclusion Argatroban as adjuvant therapy can inhibit PAG, improve curative effect and reduce the incidence of MACCE in treatment of acute cerebral infarction.
Keywords：ArgatrobanAcute cerebral infarctionMajor adverse cardiovascular and cerebrovascular eventsPlatelet aggregation rate
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 1241-1242,1245 )